Pulmonary hemorrhage and acute pulmonary thromboembolism after abciximab administration

• Published in: The American journal of emergency medicine 2013-02, Vol.31 (2), p.450.e1-450.e2
• Main Authors: Conrotto, Federico, MD, Scacciatella, Paolo, MD, Usmiani, Tullio, MD, Grasso, Costanza, MD, Ebrille, Elisa, MD, D'Amico, Maurizio, MD, Marra, Sebastiano, MD
• Format: Article
• Language: English
• Subjects: Acute Disease; Aged; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Anticoagulants; Anticoagulants - adverse effects; Anticoagulants - therapeutic use; Blood platelets; Combined Modality Therapy; Drug therapy; Drug Therapy, Combination; Emergency; Emergency medical care; Heart attacks; Hemoptysis - chemically induced; Hemoptysis - therapy; Hemorrhage; Humans; Immunoglobulin Fab Fragments - adverse effects; Immunoglobulin Fab Fragments - therapeutic use; Intubation; Male; Mortality; Myocardial infarction; Myocardial Infarction - drug therapy; Myocardial Infarction - surgery; Patients; Percutaneous Coronary Intervention - methods; Postoperative Hemorrhage - chemically induced; Postoperative Hemorrhage - diagnosis; Postoperative Hemorrhage - therapy; Pulmonary Embolism - diagnosis; Pulmonary Embolism - drug therapy; Pulmonary Embolism - etiology; Thromboembolism; Veins & arteries
• ISSN: 0735-6757; 1532-8171
• DOI: 10.1016/j.ajem.2012.06.018

Successful percutaneous coronary intervention (PCI) with a drug-eluting stent was able to restore a thrombolysis in myocardial infarction grade 3 flow in the left anterior descending artery. To reverse the effects of abciximab, we decided to administer platelet transfusion and shortly discontinue DAPT and anticoagulation therapy. [...]concerns about the hemorrhagic risks exposed the patient to a significant increase of thrombotic risk [11] and caused the subsequent PE.